TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01413607

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Quill knotless tissue-closure device
Description: The Quill knotless tissue-closure device is a barbed suture that allows the surgeon to keep tissue approximation without maintaining tension on the suture.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 2-0 absorbable vicryl suture
Description: In the control group a traditional 2-0 absorbable vicryl suture (Ethicon) will be used to close the central defect in the kidney.
Study: NCT04701164

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ANX005
Description: Solution for intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ANX005
Description: Solution for intravenous infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Solution for intravenous infusion
Study: NCT00397774

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical exercise
Description: Physical exercise twice a week for 8 weeks, and best supportive care
Study: NCT01896999

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy
Study: NCT00397774

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: best supportive care

Intervention type: OTHER
Group type: OTHER
Intervention: best supportive care
Study: NCT04440670

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: autologous cord blood mononuclear cells
Description: preterm neonates less than 28 weeks are assigned to receive intravenous autologous cord blood mononuclear cells infusion (5×107cells/kg) within 24 hours after birth
Study: NCT01896999

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy
Study: NCT04440670

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: preterm neonates less than 28 weeks are assigned to receive normal saline within 24 hours after birth
Study: NCT01896999

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood
Study: NCT06699719

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Expressive writing
Description: Participants are asked to complete four 20-minute sessions of a writing task on consecutive days, which is sent to their email address via an online link. Participants are instructed for the next 20 minutes to please use the provided box to write their very deepest thoughts and feelings about a negative issue or personal problem that they are currently being affected by. In their writing, they are encouraged to let go and explore their emotions and thoughts regarding this issue or problem, and to not worry about spelling or grammar. They are asked to consider setting a timer or have a clock handy to make sure they write for 20 minutes. Instructions are accompanied by a text box, which allows participants to write freely for the allotted time.
Study: NCT01896999

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brentuximab Vedotin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brentuximab Vedotin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brentuximab Vedotin
Description: Given IV
Study: NCT04537208

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CoV2 preS dTM-AF03 (low-dose)
Description: Pharmaceutical form: liquid; route of administration: intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CoV2 preS dTM-AF03 (low-dose)
Description: Pharmaceutical form: liquid; route of administration: intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CoV2 preS dTM-AF03 (high-dose)
Description: Pharmaceutical form: liquid; route of administration: intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CoV2 preS dTM-AF03 (high-dose)
Description: Pharmaceutical form: liquid; route of administration: intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CoV2 preS dTM-AS03 (low-dose)
Description: Pharmaceutical form: liquid; route of administration: intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CoV2 preS dTM-AS03 (low-dose)
Description: Pharmaceutical form: liquid; route of administration: intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CoV2 preS dTM-AS03 (high-dose)
Description: Pharmaceutical form: liquid; route of administration: intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CoV2 preS dTM-AS03 (high-dose)
Description: Pharmaceutical form: liquid; route of administration: intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CoV2 preS dTM (high-dose) without adjuvant
Description: Pharmaceutical form: liquid; route of administration: intramuscular injection

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (0.9% normal saline)
Description: Pharmaceutical form: liquid; route of administration: intramuscular injection

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (0.9% normal saline)
Description: Pharmaceutical form: liquid; route of administration: intramuscular injection
Study: NCT02256384

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Respiratory Acoustic Monitor
Description: Examine the reliability and accuracy of the respiratory acoustic monitor.
Study: NCT04564807

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Web-Based Insomnia Education Program
Description: Participants will be given access to a web-based program on sleep education to read at their own pace during the 9-week intervention period. The program content overlaps with SHUTi on the following topics: insomnia symptoms, impacts, and causes, basic sleep improvement strategies, and when to see a doctor. The information is akin to that found on WebMD or National Sleep Foundation website. Unlike the SHUTi program, the information is fixed, accessible immediately (no week-to-week information unlocking) and there are no customized bedtime or wake-time suggestions based on sleep diary data.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SHUTi Intervention
Description: Sleep Healthy Using the Internet (SHUTi) is a well-validated version of e-CBT-I comprised of 6 weekly educational modules and daily sleep diaries. Participants will have 9 weeks to complete 6 once-weekly educational cores. Cores consist of: insomnia overview, sleep restriction, stimulus control, cognitive restructuring, sleep hygiene, and relapse prevention, and last approximately 45 minutes each. Participants will receive weekly objectives, as well as review and feedback on the previous core's assignments and sleep diary data, new material, assignments, and a summary. These features are supplemented with interactive features (i.e., personalized goal-setting, video vignettes). Participants receive daily emails prompting them to complete the 11-item sleep and alcohol use diary daily during the intervention.
Study: NCT03905148

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lifirafenib
Description: RAF Dimer Inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lifirafenib
Description: RAF Dimer Inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mirdametinib
Description: MEK Inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mirdametinib
Description: MEK Inhibitor
Study: NCT00210353

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: chlorambucil (drug)
Description: chlorambucil 6 mg/m2 daily during the first 6 weeks of treatment, two weeks rest, chlorambucil 6 mg/m2 daily during the first two of a four weeks cycles (total of 4 cycles)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab+chlorambucil
Description: rituximab 375 mg/m2 iv, d1, 8, 15, 22, chlorambucil 6 mg/m2 os, daily during the first 6 weeks of treatment, ; two weeks rest; chlorambucil 6 mg/m2 os, daily during the first two of a four weeks cycles (total of 4 cycles) rituximab 375 mg/m2 iv at day 1 of each cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab
Description: rituximab 375 mg/m2 iv on days 1, 8, 15, 22, 56, 84, 112, 140
Study: NCT02030925

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IW-3718

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Study: NCT01541943

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: Once daily, administered orally, 8 week

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Losartan
Description: Once daily, administered orally, 8 week

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Once daily, administered orally, 8 week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HL-040XC
Description: Once daily, administered orally, 8 week
Study: NCT02615938

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine sulfate
Description: Apply drug to modify lysosomal pH

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine sulfate
Description: Apply drug to modify lysosomal pH

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Apply Placebo not to modify lysosomal pH

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Apply Placebo not to modify lysosomal pH
Study: NCT04046016

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Liporaxel and microdose 18F-Liporaxel administration study was conducted in two breast cancer patients. Therapeutic dose of Liporaxel was 200 mg/m2 and 18F-Liporaxel was 0.98-2.9 μg (185-555 MBq).
Study: NCT01263431

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hemorrhoidectomy
Description: Each of the main haemorrhoid is dissected and the apex is ligated and then cut, near to the dentate line

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hemorrhoidal dearterialization
Description: A special instrument (THD, G.F., Medical Division, Correggio, Italy )with an incorporated Doppler probe is used to detected the six terminal branches of the superior rectal artery which are ligated above the dentate line, then a running suture is performed in order to obtain a mucopexy
Study: NCT00113399

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: filgrastim

Intervention type: DRUG
Group type: OTHER
Intervention: cisplatin
Study: NCT04019574

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IV Placebo as a bolus injection
Study: NCT02533739

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Cognitive and neuropsychological assesment
Study: NCT00113399

Intervention type: DRUG
Group type: OTHER
Intervention: cisplatin

Intervention type: DRUG
Group type: OTHER
Intervention: docetaxel

Intervention type: DRUG
Group type: OTHER
Intervention: fluorouracil

Intervention type: DRUG
Group type: OTHER
Intervention: paclitaxel

Intervention type: DRUG
Group type: OTHER
Intervention: paclitaxel

Intervention type: RADIATION
Group type: OTHER
Intervention: radiation therapy
Study: NCT02533739

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive and neuropsychological assesment
Study: NCT01106651

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin 100 mg
Description: One 100 mg over-encapsulated tablet orally (by mouth) once daily for 104 weeks with/without stable doses of antihyperglycemic agent(s) taken at the time of study entry.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin 300 mg
Description: One 300 mg over-encapsulated tablet orally (by mouth) once daily for 104 weeks with/without stable doses of antihyperglycemic agent(s) taken at the time of study entry.
Study: NCT01896999

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brentuximab Vedotin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brentuximab Vedotin
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT
Study: NCT03326765

Intervention type: OTHER
Group type: OTHER
Intervention: Questionnaires
Description: * Epworth sleepiness scale~* Pittsburgh sleep quality Index (PSQI)~* EQ-5D Adults~* Pediatric Daytime Sleepiness scale (PDSS)~* Sleep disturbance Scale for Children (SDSC~* EQ-5D Children~* Sleaping diary

Intervention type: OTHER
Group type: OTHER
Intervention: Questionnaires
Description: * Epworth sleepiness scale~* Pittsburgh sleep quality Index (PSQI)~* EQ-5D Adults~* Pediatric Daytime Sleepiness scale (PDSS)~* Sleep disturbance Scale for Children (SDSC~* EQ-5D Children~* Sleaping diary

Intervention type: PROCEDURE
Group type: OTHER
Intervention: electroencephalogram (EEG)
Description: is an electrophysiological monitoring method to record electrical activity of the brain

Intervention type: PROCEDURE
Group type: OTHER
Intervention: electroencephalogram (EEG)
Description: is an electrophysiological monitoring method to record electrical activity of the brain

Intervention type: PROCEDURE
Group type: OTHER
Intervention: polysomnography
Description: type of sleep study, is a multi-parametric test used in the study of sleep and as a diagnostic tool in sleep medicine
Study: NCT01896999

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT
Study: NCT01106651

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antihyperglycemic agent(s)
Description: Stable doses of antihyperglycemic agents (sulfonylurea agent, thiazolidinediones, dipeptidyl peptidase 4 \[DPP-4\] inhibitors, metformin, insulin \[all types\]) and their combinations (sulfonylurea agent and insulin \[all types\], metformin and insulin \[all types\], metformin and sulfonylurea, alpha glucosidase inhibitors, thiazolidinediones, dipeptidyl peptidase 4 \[DPP-4\]) are used as per protocol specifications.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antihyperglycemic agent(s)
Description: Stable doses of antihyperglycemic agents (sulfonylurea agent, thiazolidinediones, dipeptidyl peptidase 4 \[DPP-4\] inhibitors, metformin, insulin \[all types\]) and their combinations (sulfonylurea agent and insulin \[all types\], metformin and insulin \[all types\], metformin and sulfonylurea, alpha glucosidase inhibitors, thiazolidinediones, dipeptidyl peptidase 4 \[DPP-4\]) are used as per protocol specifications.
Study: NCT01896999

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study: NCT01106651

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Antihyperglycemic agent(s)
Description: Stable doses of antihyperglycemic agents (sulfonylurea agent, thiazolidinediones, dipeptidyl peptidase 4 \[DPP-4\] inhibitors, metformin, insulin \[all types\]) and their combinations (sulfonylurea agent and insulin \[all types\], metformin and insulin \[all types\], metformin and sulfonylurea, alpha glucosidase inhibitors, thiazolidinediones, dipeptidyl peptidase 4 \[DPP-4\]) are used as per protocol specifications.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One matching placebo capsule orally once daily for 104 weeks with/without stable doses of antihyperglycemic agent(s) taken at the time of study entry.
Study: NCT01779856

Intervention type: DEVICE
Group type: OTHER
Intervention: REVEAL Insertable Cardiac Monitor (ICM)
Study: NCT05551923

Intervention type: OTHER
Intervention: intestinal flora disturbance
Description: To observe the clinical prognosis of acute cerebral hemorrhage after enterobacterial disorder
Study: NCT04345861

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxychloroquine + placebo
Description: hydroxychloroquine : 800mg(Day1) then 600 mg (Day 2 to Day 11)
Study: NCT03335215

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cognitive remediation
Description: The innovative nature of this program is that it integrates both neuropsychological psychoeducation, the principles of reeducation of altered cognitive functions and the setting in addictological context benefiting from the interactions of the group situation. Thus, during the three months of REMED management, six modules corresponding to six altered cognitive domains that may have an impact on the maintenance of the therapeutic contract will be offered to patients. The REMED group will benefit from cognitive remediation of episodic memory disorders, executive and attentional functions, and the theory of the mind integrating psychoeducation, training and systematic situations related to an alcoholic context. The different procedures of neuropsychological management (facilitation, use of preserved capacities and compensation) will help to integrate the concepts and addictological strategies necessary to maintain the therapeutic contract taking into account cognitive impairments.
Study: NCT01896999

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET
Study: NCT03318406

Intervention type: DEVICE
Intervention: Bronchoscopic Thermal Vapor Ablation
Description: Bronchoscopic vapor delivery to airway segment(s) targeted for treatment
Study: NCT03532100

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Torsionally adaptive prosthesis with 0:1 coupling ratio
Description: The torsionally adaptive prosthesis can be programmed to couple the motion between the transverse- and sagittal-planes. A coupling ratio (transverse:sagittal) of 0:1 means there will be no coupling between the transverse- and sagittal-plane motion. That is, regardless of any motion in the sagittal plane, there will be zero motion in the transverse plane.
Study: NCT01377987

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetazolamide
Description: 4 mg/kg, once daily before bed, for 7 days
Study: NCT04345861

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hydroxychloroquine + azithromycin
Description: Combination hydroxychloroquine : 800mg(Day1) then 600 mg (Day 2 to Day 11) Azithromycin 500mg (day 1) then 250 mg (Day 2 to Day 5)
Study: NCT03603587

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: biopsy
Description: Biopsy 4 to 5 mm from the distal part of the tips of the excision pieces. Three biopsies of 3 mm, made with punch, occipital hair zone (ZT) A completely painless sample, using a swab (soaked with a buffer solution) on the scalp of the ZH and ZT zone.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: blood sample
Description: Blood sample will be collected for performed for HIV serology, B and C hepatitis.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: questionnaire on sun exposure
Description: Questionnaire on sun exposure will be completed by patients.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: examination of the scalp
Description: A complete examination of the scalp will be completed by dermatologist.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Norwood scale
Description: Norwood scale measure the evolution of baldness. It will be completed by dermatologist.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: questionnaire of clinicals signs
Description: Questionnaire of clinicals signs will be completed by dermatologist and patient.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: scinexa score
Description: It's a assessment score of skin aging. It will be completed by dermatologist.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: questionnaire of the history of the hair loss
Description: Questionnaire of the history of the hair loss will be completed by dermatologist and patient.
Study: NCT01377987

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 4 mg/kg, once daily before bed, for 7 days
Study: NCT04500080

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PE Intervention
Description: Each single exercise session will last for one hour and will consist of a combination of the following elements:~* Aerobic Exercise (AE): 20-30 minutes at moderate-high intensity, from 60 to 80% of the maximum heart rate (% HRmax).~* Resistance Exercise (RE): 30 minutes of strength activity of the major muscle groups.~* Neuromotor Exercise (NE): will be integrated with strength exercises and will consist of jumping, balance and coordination activities
Study: NCT02453945

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Adjustable Support Bra
Description: A ClearPoint Medical support bra
Study: NCT04181593

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omega 3 fatty acid
Description: Omega 3 fatty acid Softgels

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Mineral oil Softgels
Study: NCT03197987

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endocuff
Description: Endocuff-assisted colonoscopy